medigraphic.com
Revista Médica Sinergia

2019, Number 06

<< Back Next >>

Revista Médica Sinergia 2019; 4 (06)

New pharmacological strategies for the treatment in smoking cessation

Leiva GK, Quesada VV

Language: Spanish
References: 23
Page: 73-80
PDF size: 396.85 Kb.


ABSTRACT

Nowadays, smoking, remains the worldwide leading cause of death by preventable disease. As smoking is physiologically and psychologically addictive, the quitting success rates remain low. As part of the quitting process, the pharmacology therapy must go hand in hand with behavioral therapy. The FDA has approved three first-line drugs for smoking cessation: nicotine replacement therapy (NRT), bupropion and varenicline. Nicotine inhalers have been shown to be as effective as other commercial forms of nicotine replacement therapy. Bupropion, initially commercialize as an antidepressant, has shown to be highly effective in smoking cessation. This drug decreases the anxiety that patients experience when quitting smoking, in addition to control weight gain during the process. Varenicline is the treatment of higher efficacy, being superior than NRT and bupropion, due to its dual effect on nicotinic acetylcholine receptors.


REFERENCES

  1. Vogeler T, McClain C, Evoy K. Combination bupropion SR and varenicline for smoking cessation: a systematic review. The American Journal of Drug and Alcohol Abuse. 2016; 42(2): 129- 139. https://doi.org/10.3109/00952990.2015.1117480

  2. Benli A, Erturhan S, Oruc M, Kalpakci P, Sunay D, Demirel Y. A comparison of the efficacy of varenicline and bupropion and an evaluation of the effect of the medications in the context of the smoking cessation programme. Tobacco Induced Diseases. 2017; 15(February): 10.https://doi.org/10.1186/s12971-017- 0116-0

  3. Hakan T, Murat A, Özgür D, Metin Ç. Success Rate of Pharmacological Therapies Used for Smoking Cessation and Factors that Affect Smoking Cessation Rates. European Journal of General Medicine. 2015; 12(2): 125-130. https://doi.org/10.15197/sabad.1.12.26

  4. Barua R, Rigotti N, Benowitz N, Cummings K, Jazayeri M, Morris P et al. 2018 ACC Expert Consensus Decision Pathway on Tobacco Cessation Treatment. Journal of the American College of Cardiology. 2018; 72(25): 3332-3365. https://doi.org/10.1016/j.jacc.2018.10.027

  5. Liu M, Li X, Fan R, Liu X, Wang J. A Systematic Analysis of Candidate Genes Associated with Nicotine Addiction. BioMed Research International. 2015; 2015: 313709.https://doi.org/10.1155/2015/313709

  6. Regalado-Pineda J, Lara-Rivas G, Osio-Echánove J, Ramírez-Venegas A. Tratamiento actual del tabaquismo. Salud Pública de México. 2007; 49(0036-3634): s270-s279.https://doi.org/10.1590/S0036- 36342007000800018

  7. Hartmann-Boyce J, Chepkin S, Ye W, Bullen C, Lancaster T. Nicotine replacement therapy versus control for smoking cessation. Cochrane Database of Systematic Reviews. 2018; (5): CD000146. https://doi.org/10.1002/14651858.CD000146.pub5

  8. George T. Nicotine and Tobacco. Goldman-Cecil Medicine. 25th ed. Philadelphia: Elsevier/Saunders; 2016. p 145-149.

  9. Benowitz N, Brunetta P. Smoking Hazards and Cessation. Murray & Nadel’s textbook of respiratory medicine. 6th ed. Philadelphia: Elsevier; 2016. 807-821.e3.https://doi.org/10.1016/B978-1-4557-3383- 5.00046-4

  10. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database of Systematic Reviews. 2013; (5): CD009329. https://doi.org/10.1002/14651858.CD009329.pub2

  11. Lerman C, Shields P, Wileyto E, Audrain J, Hawk L, Pinto A et al. Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial. Health Psychology. 2003; 22(5): 541-548. https://doi.org/10.1037/0278-6133.22.5.541

  12. Díaz J, Jiménez C. Tratamiento farmacológico del tabaquismo. Información Terapéutica del Sistema Nacional de Salud. 2008; 32(3). p71-82.

  13. Issa J, Santos P, Vieira L, Abe T, Kuperszmidt C, Nakasato M et al. Smoking cessation and weight gain in patients with cardiovascular disease or risk factor. International Journal of Cardiology. 2014; 172(2): 485- 487. https://doi.org/10.1016/j.ijcard.2014.01.055

  14. Bagdas D, Alkhlaif Y, Jackson A, Carroll F, Ditre J, Damaj M. New insights on the effects of varenicline on nicotine reward, withdrawal and hyperalgesia in mice. Neuropharmacology. 2018; 138: 72- 79. https://doi.org/10.1016/j.neuropharm.2018.05.025

  15. Kazan T, Charntikov S. Individual differences in responding to bupropion or varenicline in a preclinical model of nicotine self-administration vary according to individual demand for nicotine. Neuropharmacology. 2019; 148: 139-150. https://doi.org/10.1016/j.neuropharm.2018.12.031

  16. McDonough M. Update on medicines for smoking cessation. Australian Prescriber. 2015 ;38(4): 106- 111. https://doi.org/10.18773/austprescr.2015.038

  17. Peña G. P, Zagolin B. M. Vareniclina. Revista chilena de enfermedades respiratorias. 2017; 33(3): 212- 215. https://doi.org/10.4067/s0717-73482017000300212

  18. Hays J, Ebbert J. Varenicline for Tobacco Dependence. New England Journal of Medicine. 2008; 359(19): 2018-2024. https://doi.org/10.1056/NEJMct0800146

  19. Steinberg M, Lu S, Williams J. Varenicline for smoking reduction in smokers not yet ready to quit: A double-blind, proof-of-concept randomized clinical trial. Addictive Behaviors. 2018; 84: 20- 26. https://doi.org/10.1016/j.addbeh.2018.03.026

  20. Cahill K, Lindson-Hawley N, Thomas K, Fanshawe T, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database of Systematic Reviews. 2016; (5): CD006103.https://doi.org/10.1002/14651858.CD006103.pub7

  21. Anthenelli R, Benowitz N, West R, St Aubin L, McRae T, Lawrence D et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. The Lancet. 2016; 387(10037): 2507-2520. https://doi.org/10.1016/S0140-6736(16)30272-0

  22. Seguí Díaz M. ¿Cuáles son los efectos cardiovasculares y neuropsiquiátricos de la vareniclina en el tratamiento del tabaquismo?. SEMERGEN - Medicina de Familia. 2016; 42(6): e67- e68. https://doi.org/10.1016/j.semerg.2015.11.004

  23. Kotz D, Simpson C, Viechtbauer W, van Schayck O, West R, Sheikh A. Cardiovascular and neuropsychiatric safety of varenicline and bupropion compared with nicotine replacement therapy for smoking cessation: study protocol of a retrospective cohort study using the QResearch general practice database. BMJ Open. 2014; 4(8): e005281-e005281. https://doi.org/10.1136/bmjopen-2014-005281.




2020     |     www.medigraphic.com